CABOMETYX (cabozantinib) is now available on the PBS for eligible patients with Stage IV non-clear cell renal cell carcinoma (RCC), marking a new treatment option for those previously without access.
Christine Cockburn, CEO of Rare Cancers Australia, welcomed the announcement, saying it was a positive step towards equitable access for approximately 800 people living with Stage IV non-clear cell RCC in Australia.
The earlier listing for the medicine was only applicable to clear cell subtypes.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Sep 24
